Biomarker testing in MCI patients—deciding who to test

Biomarker testing in MCI patients—deciding who to test

Abstract Background We aimed to derive an algorithm to define the optimal proportion of patients with mild cognitive impairment (MCI) in whom cerebrospinal fluid (CSF) testing is of added prognostic value. Methods MCI patients were selected from the Amsterdam Dementia Cohort (n = 402). Three-year pr...

Full description

Bibliographic Details
Main Authors: Ingrid S. van Maurik, Hanneke F. M. Rhodius-Meester, Charlotte E. Teunissen, Philip Scheltens, Frederik Barkhof, Sebastian Palmqvist, Oskar Hansson, Wiesje M. van der Flier, Johannes Berkhof
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Alzheimer’s Research & Therapy
Subjects:
Biomarkers
Decision support
MCI
Online Access:https://doi.org/10.1186/s13195-020-00763-7

Internet

https://doi.org/10.1186/s13195-020-00763-7

Similar Items